Epilepsy Trial, Recruiting NCT05420935 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT05420935
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 70 years old
  • People who had an allergic reaction during surgery at any point in the last 10 years, regardless of how severe it was, what caused it, or what type of anaesthetic was used
  • People who have already attended a combined allergy and anaesthesia specialist appointment at the trial centre
  • (For one group of participants) People whose allergy skin tests showed a positive reaction to one of the suspected substances — either a muscle relaxant drug or an antibiotic — during their allergy consultation
  • (For the other group of participants) People whose blood tests — taken at the time of the allergic reaction or at a specialist consultation — detected a specific type of antibody (called IgG) directed against one of the suspected substances, which may include a muscle relaxant, antibiotic, or antiseptic

Who may not be able to join:

  • People who have not provided written consent to take part
  • People who are legally under guardianship or a similar form of legal protection
  • People who do not have social security coverage
  • People who are pregnant or breastfeeding
  • People currently receiving treatment that suppresses the immune system, or currently undergoing chemotherapy
  • People with active, serious heart failure
  • People already taking part in another interventional research study that has an exclusion period
  • (For one group) People taking blood-thinning medications, whether by mouth or injection
  • (For one group) People taking two different antiplatelet (blood-clotting-reducing) medications at the same time
  • (For one group) People who have previously had a sternotomy (surgery where the breastbone is cut open)
  • (For one group) People who have previously had radiation therapy to the chest area
  • (For one group) People with a known allergy to local anaesthetic agents or iodine-based skin products
  • (For one group) People with a history of significant skin damage or lesions over the breastbone area
  • (For one group) People whose recent blood tests (within the past 2 months) show white blood cell or platelet counts below the required levels (confirm with trial site)
  • (For the other group) People who experience a significant drop in blood pressure when standing up (orthostatic hypotension)
  • (For the other group) People who have donated blood in the 6 to 8 weeks before joining the trial
  • (For the other group) People whose recent blood test (within the past 2 months) shows haemoglobin levels below the required level for their sex (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aurelie Gouel, MD, PhD, Assistance Publique - Hôpitaux de Paris

Phone: 00-33-1-40-25-83-55

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 April 2023
Est. completion
12 April 2033

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Obtain sequences of gene producers (VH and VL pairs) coding for the variable part of anti-drug antibodies, thanks to the isolation of B lymphocytes of antibodies directed against the responsible molecule, from blood cells or bone marrow

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov